| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C17H25N |
| Molar mass | 243.394 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
3-Methyl-PCPy (3-Me-PCPy) is an arylcyclohexylamine derivative with an unusual spectrum of pharmacological effects, acting as both a potent NMDA antagonist and also a triple reuptake inhibitor which inhibits reuptake of all three monoamine neurotransmitters serotonin, dopamine and noradrenaline. It also acts as a high affinity sigma receptor ligand, selective for the σ2 subtype. It produces both stimulant and dissociative effects in animal behavioural studies.
In in vitro binding assays, 3-Me-PCPy displays high affinities across monoamine reuptake transporters alongside the NMDA receptor complex. Unusually for an arylcyclohexylamine dissociative, its affinity for the serotonin transporter (SERT) is approximately ten-fold higher than its affinity for the NMDA receptor pore.
| Target site | Assay / Site | Ki (nM) |
|---|---|---|
| Serotonin transporter (SERT) | Monoamine reuptake | 5.6 |
| Dopamine transporter (DAT) | Monoamine reuptake | 39.0 |
| Norepinephrine transporter (NET) | Monoamine reuptake | 45.0 |
| NMDA receptor | Dizocilpine (MK-801) site | 52.3 |
3-Methyl-PCPy is covered by drug analogue laws in various jurisdictions (UK, Germany, Japan, Australia etc.) as a generic arylcyclohexylamine derivative, and a structural isomer of phencyclidine.
| σ1 |
|
|---|---|
| σ2 |
|
| Unsorted |
|
See also: Receptor/signaling modulators | |
This hallucinogen-related article is a stub. You can help Wikipedia by adding missing information. |